Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3 Diabetes Mellitus 2 Vomiting 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostatic Neoplasms 1 Premature Birth 1 Pre-Eclampsia 1 Polycystic Ovary Syndrome 1 Parathyroid Neoplasms 1 Neoplasms 1 Medulloblastoma 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Hairy Cell 1 Leukemia, B-Cell 1 Leiomyosarcoma 1 Hyperparathyroidism, Primary 1 Hot Flashes 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Erectile Dysfunction 1 Cognitive Dysfunction 1 Carcinoma, Renal Cell 1

Interventions

Sunitinib 20 Nivolumab 16 cabozantinib 12 Sorafenib 12 pembrolizumab 11 pazopanib 9 Ipilimumab 9 Interferon-alpha 9 belzutifan 8 Everolimus 8 lenvatinib 7 Bevacizumab 7 aldesleukin 6 Magnetic Resonance Spectroscopy 6 Axitinib 6 atezolizumab 5 Interferon alpha-2 4 temsirolimus 3 Specimen Handling 3 Radiosurgery 3 Nephrectomy 3 Interleukin-2 3 tivozanib 2 durvalumab 2 avelumab 2 Saline Solution 2 G250 monoclonal antibody 2 Fluorouracil 2 Chemotherapy, Adjuvant 2 CTLA-4 Antigen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Renal Cell × Tablets × Clear all

NCT01865747 2021-04-27

METEOR

Exelixis

Phase 3 Completed

658 enrolled 15 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡